A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Strata Critical Medical, Inc.
SRTA
$417M
Mkt Cap
$5.04
-0.98%
Strata Critical Medical, Inc. (SRTA) has a current P/E ratio of 10.1, compared to its historical median P/E of 9.7. The stock is currently considered Expensive based on its historical valuation range.
Strata Critical Medical, Inc. (SRTA) has a 5-year average return on invested capital (ROIC) of -9.0%. This is below average and may indicate limited pricing power.
Strata Critical Medical, Inc. (SRTA) has a market capitalization of $417M. It is classified as a small-cap stock.
Strata Critical Medical, Inc. (SRTA) does not currently pay a regular dividend.
Based on historical P/E analysis, Strata Critical Medical, Inc. (SRTA) appears expensive. The current P/E of 10.1 is 3% above its historical median of 9.7.
Strata Critical Medical, Inc. (SRTA) operates in the Services-Health Services industry, within the Healthcare sector.
Strata Critical Medical, Inc. (SRTA) reported annual revenue of $197 million in its most recent fiscal year, based on SEC EDGAR filings.
Business Overview Strata Critical Medical, Inc.(f/k/a Blade Air Mobility, Inc.) (“Strata” or the “Company”) is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery. Strata’s core services include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions (“Trinity”) and Keystone Perfusion Services LLC (“Keystone”) brands.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 197M | 197M | 147M | 225M | 146M | 51M |
| Net Income | 41M | 41M | -27M | -56M | -27M | -40M |
| EPS | $0.50 | $0.50 | $-0.35 | $-0.76 | $-0.38 | $-0.93 |
| Free Cash Flow | -59M | -59M | -33M | -34M | -38M | -16M |
| ROIC | -8.0% | 14.8% | -12.3% | -23.9% | -9.9% | -13.7% |
| Gross Margin | 20.9% | 20.9% | 20.2% | 18.7% | 15.2% | 20.8% |
| Debt/Equity | 0.00 | 0.17 | 0.16 | 0.26 | 0.00 | 0.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -22M | -22M | -23M | -68M | -54M | -24M |
| Operating Margin | -11.3% | -11.3% | -15.3% | -30.3% | -36.6% | -47.7% |
| ROE | 14.8% | 16.5% | -12.3% | -23.9% | -9.9% | -13.7% |
| Shares Outstanding | 83M | 83M | 78M | 74M | 72M | 43M |
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 23M | 51M | 146M | 225M | 147M | 197M | 197M |
| Gross Margin | 9.9% | 20.8% | 15.2% | 18.7% | 20.2% | 20.9% | 20.9% |
| R&D | 861K | 1.7M | 5.5M | 4.6M | N/A | N/A | N/A |
| SG&A | 9.3M | 30M | 63M | 95M | 51M | 61M | 61M |
| EBIT | -10M | -24M | -54M | -68M | -23M | -22M | -22M |
| Op. Margin | -44.2% | -47.7% | -36.6% | -30.3% | -15.3% | -11.3% | -11.3% |
| Net Income | -10M | -40M | -27M | -56M | -27M | 41M | 41M |
| Net Margin | -43.4% | -79.3% | -18.7% | -24.9% | -18.6% | 21.0% | 21.0% |
| Non-Recurring | 0 | 0 | -2.2M | 8K | 0 | -5.2M | -5.2M |
| Returns on Capital | |||||||
| ROIC | -91.7% | -13.7% | -9.9% | -23.9% | -12.3% | 14.8% | -8.0% |
| ROE | -91.7% | -13.7% | -9.9% | -23.9% | -12.3% | 16.5% | 14.8% |
| ROA | -57.4% | -11.9% | -8.4% | -19.0% | -10.6% | 14.2% | 12.7% |
| Cash Flow | |||||||
| Op. Cash Flow | -11M | -16M | -37M | -32M | -2.5M | -49M | -49M |
| Free Cash Flow | -11M | -16M | -38M | -34M | -33M | -59M | -59M |
| Owner Earnings | -12M | -26M | -51M | -52M | -28M | -75M | -75M |
| CapEx | 377K | 297K | 730K | 2.1M | 31M | 9.6M | 9.6M |
| Maint. CapEx | 526K | 596K | 5.7M | 7.1M | 6.0M | 8.2M | 8.2M |
| Growth CapEx | 0 | 0 | 0 | 0 | 25M | 1.4M | 1.4M |
| D&A | 526K | 596K | 5.7M | 7.1M | 6.0M | 8.2M | 8.2M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 244K | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.1% | N/A | 0.0% |
| Stock-Based Comp | 490K | 9.6M | 8.3M | 13M | 20M | 18M | 18M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | -9.8M | N/A | -192M | N/A | N/A | N/A | -264K |
| Cash & Equiv. | 12M | 2.6M | 41M | 28M | 263K | 264K | 264K |
| Long-Term Debt | N/A | N/A | 0 | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.21 | 0.15 | 0.00 | 0.26 | 0.16 | 0.17 | 0.00 |
| Interest Coverage | N/A | -2007.8 | N/A | -8.1 | -3.1 | -5.3 | -5.3 |
| Equity | 11M | 291M | 274M | 234M | 222M | 279M | 279M |
| Total Assets | 18M | 336M | 325M | 295M | 257M | 325M | 325M |
| Total Liabilities | 6.6M | 45M | 51M | 61M | 35M | 46M | 46M |
| Intangibles | 533K | 38M | 86M | 61M | 24M | 136M | 136M |
| Retained Earnings | -37M | -76M | -104M | -160M | -187M | -146M | -146M |
| Working Capital | 8.0M | 282M | 192M | 171M | 138M | 106M | 106M |
| Current Assets | 14M | 295M | 218M | 206M | 161M | 126M | 126M |
| Current Liabilities | 6.3M | 13M | 27M | 35M | 23M | 20M | 20M |
| Per Share Data | |||||||
| EPS | -0.40 | -0.93 | -0.38 | -0.76 | -0.35 | 0.50 | 0.50 |
| Owner EPS | -0.17 | -0.60 | -0.71 | -0.70 | -0.36 | -0.91 | -0.91 |
| Book Value | 0.16 | 6.77 | 3.83 | 3.18 | 2.84 | 3.37 | 3.37 |
| Cash Flow/Share | -0.15 | -0.36 | -0.52 | -0.44 | -0.03 | -0.59 | 0.60 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 70.6M | 43.1M | 71.7M | 73.8M | 78.0M | 82.7M | 82.7M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 9.7 | 10.1 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 71.4 | 1.2 | 0.9 | 1.1 | 1.6 | 1.4 | 1.5 |
| Price/Sales | 30.1 | 8.9 | 2.9 | 1.1 | 1.8 | 1.7 | 2.1 |
| FCF Yield | -1.4% | -4.4% | -15.7% | -13.0% | -9.7% | -14.5% | -14.0% |
| Market Cap | 792M | 358M | 242M | 266M | 344M | 403M | 417M |
| Avg. Price | 9.99 | 10.50 | 5.96 | 3.41 | 3.35 | 4.03 | 5.04 |
| Year-End Price | 11.22 | 8.32 | 3.37 | 3.60 | 4.41 | 4.87 | 5.04 |
Strata Critical Medical, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Strata Critical Medical, Inc. trades at 10.1x trailing earnings, compared to its 15-year median P/E of 9.7x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 19.2%.
Strata Critical Medical, Inc. (SRTA) has a net profit margin of 21.0%. This is a strong margin indicating high profitability.
Strata Critical Medical, Inc. (SRTA) generated $-59 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Strata Critical Medical, Inc. (SRTA) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
Strata Critical Medical, Inc. (SRTA) reported earnings per share (EPS) of $0.50 in its most recent fiscal year.
Strata Critical Medical, Inc. (SRTA) has a return on equity (ROE) of 16.5%. This indicates the company generates strong returns for shareholders.
Strata Critical Medical, Inc. (SRTA) has a 5-year average gross margin of 19.2%. This lower margin is typical of capital-intensive or commodity businesses.
The Ledger Terminal provides 6 years of financial data for Strata Critical Medical, Inc. (SRTA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Strata Critical Medical, Inc. (SRTA) has a book value per share of $3.37, based on its most recent annual SEC filing.